Closed Solicitation · DEPARTMENT OF HEALTH AND HUMAN SERVICES
AI Summary
The National Institutes of Health intends to award a sole source contract to 10X Genomics Inc. for reagents and consumables for the Early Detection of Lung Diseases project. This acquisition follows FAR Part 13 Simplified Acquisition Procedures, allowing for a single source solicitation. Comments can be submitted to the NIH prior to the specified closing date.
This is a notice of intent, not a request for a quotation. A solicitation document will not be issued and quotations will not be requested.
The National Institutes of Health, Office of Purchasing and Contracts on behalf of the Critical Care Medicine Department intends to award a firm fixed priced contract to 10X Genomics Inc. for the acquisition of reagents and consumables required for the Early Detection of Lung Diseases (EDLI) project.
This acquisition is being conducted using policies unique to the Federal Acquisition Regulation (FAR) Part 13 –Simplified Acquisition Procedures, Subpart 13.106-1(b)(1), For purchases not exceeding the simplified acquisition threshold (SAT), contracting officers may solicit from one source if the contracting officer determines that the circumstance of the contract action deem only one source reasonably available. Contracts awarded using FAR Part 13-Simplified Acquisition Procedures are exempt from the requirements of FAR Part 6-Competition Requirements.
Comments to this announcement, referencing this posting number, may be submitted to the NIH, Clinical Center, Office of Purchasing and Contracts, prior to the closing date specified in this announcement, to the attention of Ryssa Nix, Contract Specialist via email to Ryssa.nix@nih.gov by close date.
NOTICE OF INTENT TO SOLE SOURCE – 10X GENOMICS, INC. is a federal acquisition solicitation issued by DEPARTMENT OF HEALTH AND HUMAN SERVICES. Review the full description, attachments, and submission requirements on SamSearch before the response deadline.
SamSearch Platform
AI-powered intelligence for the right opportunities, the right leads, and the right time.